StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report published on Friday. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Price Performance

NASDAQ ADXS opened at $0.02 on Friday. Ayala Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $1.49. The business has a 50-day moving average price of $0.10 and a 200-day moving average price of $0.38. The firm has a market cap of $852,600.00, a price-to-earnings ratio of 0.00 and a beta of 1.56.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.